Fulvest 250mg Injection

About

Fulvestrant is an estrogen receptor antagonist indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women. It works by binding to and degrading the estrogen receptor, thereby inhibiting estrogen-dependent tumor growth. This mechanism of action makes it effective in patients whose tumors are sensitive to hormonal manipulation and is often used in patients with disease progression following endocrine therapy.

Fulvestrant is administered as an intramuscular injection. Its unique mechanism, distinct from aromatase inhibitors, offers an alternative therapeutic option for patients who have developed resistance to other endocrine agents. Clinical studies have demonstrated its efficacy in improving progression-free survival in the specified patient population, either as monotherapy or in combination with other targeted therapies.

Uses

• Hormone receptor-positive advanced breast cancer.
• Postmenopausal women with HR-positive, HER2-negative breast cancer.
• Disease progression following endocrine therapy.
• In combination with CDK4/6 inhibitors for advanced breast cancer.

Directions For Use

Administered by a healthcare professional as an intramuscular injection. Do not self-administer.

Benefits

• Targets estrogen receptors directly.
• Effective in advanced breast cancer.
• Option for endocrine-resistant disease.
• Improves progression-free survival.
• Can be used as monotherapy or combination.
• Well-established efficacy profile.

Side Effects

• Injection site reactions (pain, swelling)
• Nausea
• Vomiting
• Fatigue
• Headache
• Hot flashes
• Arthralgia (joint pain)
• Back pain
• Anorexia
• Peripheral edema
• Asthenia (weakness)
• Urinary tract infection

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may worsen fatigue or liver-related side effects.
• Pregnancy - Contraindicated during pregnancy due to potential harm to the fetus. Effective contraception is required.
• Breastfeeding - Not recommended during breastfeeding as it may pass into breast milk and harm the infant.
• Liver - Use with caution in patients with moderate to severe hepatic impairment; dose adjustment may be necessary.
• Kidney - No specific dose adjustment required for mild to moderate renal impairment. Use with caution in severe impairment.
• Lung - No specific precautions for lung conditions, but monitor for any new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.